Kornimate/medical-research-clean huggingface dataset:
hmb cerebral palsy pilot study

Conditions: Cerebral Palsy

Summary: this is a pilot study of β-hydroxy-β-methylbutyrate (hmb) + vitamin d3 supplementation in adolescents with cerebral palsy. the primary objective is to quantify safety, compliance, and acceptability of daily combined hmb + vitamin d3 supplementation for 12 weeks in adolescents with cp. the secondary objective is to quantify changes in lower extremity muscle mass, strength, and functional mobility after daily combined hmb + vitamin d3 supplementation for 12 weeks.


Eligibility criteria:
inclusion criteria: * diagnosed with cerebral palsy * spastic or mixed tone * gmfcs level i-iii (i.e., ambulatory) * 13-17 years old * physical training level expected to remain relatively constant over the study period * ability to follow directions, including swallowing multiple pills daily and complying with reproductive risk recommendations (post-menarchal females) * within reasonable driving distance to the university of minnesota - twin cities * reads english exclusion criteria: * pregnant, lactating, or trying to become pregnant * surgery in the past 9 months * botulinum toxin injections in past 3 months * selective dorsal rhizotomy in the past 12 months * upcoming invasive treatment within the study period that may affect strength or functional mobility (e.g., surgery, botulinum toxin injections, intrathecal baclofen pump or dosage change) * liver disease or liver disorder * kidney disease or disorder * prescription drug or nutrition supplement contraindications * excessive research or medical-related radiation exposure in the past 12 months (approximately 500 mrem or greater)

Keywords: hmb vitamin d safety compliance strength muscle mass mobility β-hydroxy-β-methylbutyrate calcium β-hydroxy-β-methylbutyrate
a randomized controlled trial comparing band ligation and cyanoacrylate injection for esophageal varices

Conditions: Liver Disease

Summary: compare vbl and cyanoacrylate injection (ci) in the treatment of ev in patients with advanced liver disease regarding eradication, bleeding, mortality, complication and recurrence rates.


Eligibility criteria:
inclusion criteria: * advanced liver disease (child-pugh ≥ 8 points) * medium and/or large esophageal varices exclusion criteria: * prior endoscopic treatment. * history of shunt operation

Keywords: advanced liver disease esophageal varices band ligation cyanoacrylate injection
dental stem cells and bone tissue engineering (celsordino)

Conditions: Tooth, Impacted

Summary: the main limitation in bone regeneration is the lack of vascularization of the newly shaped tissue. the main objective of this project is to check if the simultaneous differentiation of dental mesenchymal stem cells toward osteoblastic and endothelial lineage permits to obtain a new pre-vascularized tissue engineered bone construct. we will then evaluate the boosting effect of the conditionned medium on cell differentiation and production of a prevascularized bone construct.

this project aims to develop a new pre-vascularized tissue engineered bone construct, using human cells of a simple and non invasive tissue source: dental pulp. we will isolate mesenchymal stem cells from dental tissue of wisdom teeth, extracted from patients aged between 13 and 17 years old. the objectives are: (i) to assess in combination the endothelial differentiation and osteoblastic differentiation of dental pulp stem cells (immature third molar); (ii) to study the boosting effect of the conditionned medium on cell differentiation and production of a prevascularized bone construct. the differentiation will be monitored by evaluation of biosynthesized matrix, bone mineralization (immunohistochimie, westen blot), histological response (von kossa, alizarin red) and presence and quantification of pseudo-vascular structures (angiogenesis assay), compared to reference value (commercial differentiation medium).

Eligibility criteria:
inclusion criteria: * patients aged between 13 and 17 years, who will come to dental service of university regional hospital center of nancy in order to have a tooth avulsion. * patient who has received a complete information about research organization and who is not opposed to the use of his own data. * patient who the representatives of parental authority have received a complete information about research organization and who are not opposed to the use of children's data. exclusion criteria: * patients with local or general pathology

Keywords: bone tissue engineering, dental stem cell differentiation
study of s-1 plus dc-cik for patients with advanced gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated cytokine induced killer treatment (dc-cik) plus s-1 based chemotherapy for advanced gastric cancer.


Eligibility criteria:
inclusion criteria: * histologically/cytologically confirmed recurrent or metastatic gastric or esophagogastric junctional adenocarcinoma * between 18 and 80 years old * capable of oral intake * measurable disease as defined by response evaluation criteria in solid tumors (recist) criteria * karnofsky performance status (kps) ≥ 70% * normal functions of heart, lung and bone marrow * adequate hematological profile： hemoglobin ≥ 9.0 g/dl absolute granulocyte count ≥ 1,500/mm3 platelet count ≥ 100,000/mm3 * adequate hepatic function total bilirubin level≤ 3.0 times the upper limit of normal (uln) transaminases ast (sgot) and alt (sgpt) ≤ 2.5 times uln * adequate renal function(normal serum creatinine level) * a life expectancy≥ 2 months * informed consent signed exclusion criteria: * current enrollment in another clinical study with an investigational agent. patients participating in surveys or observational studies are eligible to participate in this study * any radiotherapy or surgery within the previous 4 weeks * symptomatic brain metastasis not controlled by corticosteroids * bone marrow metastasis * active infection * serious complications * receiving a concomitant treatment with drugs interacting with s-1. the following drugs are prohibited because there may be an interaction with s-1: phenytoin, potassium warfarin , flucytosine, cimetidine and folinic acid. * pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy * ineligible for the study at the discretion of investigators

Keywords: gastric cancer s-1 dc-cik t cell
medically assisted procreation and choice of the embryo: how far would french people like to go

Conditions: Infertility

Summary: in today's context of bioethics laws revision concerning medically assisted procreation, the investigators focus on the opinion of couples resorting to in vitro fertilization on a fundamental, much debated issue ; the choice of the embryo. french lawmakers fear the investigators might be drifting towards embryo selection procedures, but no study allows us to state this is what patients request. this study aims at determining, among the population of patients who resort to medically assisted procreation in france, the ratio of patients who are willing to select the embryo due to its genetic characteristics.


Eligibility criteria:
inclusion criteria: - male and female ivf patients in the map exclusion criteria: - patient not fluent in french

Keywords: couple infertility with ivf indication genetic indication for pgd in france
antegrade screw placement technique in anterior column of acetabulum

Conditions: Acetabulum Fracture

Summary: this retrospective observational study aims to define the optimal antegrade entry point for screw placement in the anterior column fixation corridor (acfc) of the acetabulum. using fluoroscopic visualization techniques, the study examines computed tomography (ct) scans from 500 healthy adult patients to simulate screw placement and measure anatomical parameters. the goal is to determine patient-specific entry points and to assess the feasibility of screw placement using axial fluoroscopic views. the study also investigates gender-specific anatomical variations to provide insights for safer and more precise screw placement during anterior column fixation in pelvic surgery.

this study focuses on developing and validating a fluoroscopic visualization technique for identifying the optimal antegrade entry point (oaep) in the anterior column fixation corridor (acfc) of the acetabulum during pelvic surgery. using three-dimensional reconstructions from pelvic computed tomography (ct) data of 500 healthy adults, the study simulates screw placement within the acfc. a cylinder representing the screw is inserted virtually through the oaep, ensuring that it remains within the confines of the fixation corridor without breaching its boundaries. the study records anatomical measurements, including the corridor's diameter, length, and the angles required for sagittal and coronal plane inclinations to visualize the oaep. the study also examines gender-specific anatomical variations, including differences in acfc diameter, length, and required fluoroscopic angles. by defining patient-specific entry points and establishing a reliable fluoroscopic technique, this study aims to provide a practical and accessible method for anterior column fixation, minimizing complications and improving the safety and precision of screw placement in pelvic surgeries. this novel approach has the potential to offer a cost-effective alternative to more expensive navigation systems, making it widely applicable in clinical settings.

Eligibility criteria:
inclusion criteria: * patients with pelvic computed tomography (ct) scans that provide complete anatomical details of the pelvis. * patients aged 18 to 65 years. * patients with fully matured bone structures, without evidence of fractures, deformities, or prior orthopedic surgery. * patients with no history of rheumatologic disease, advanced osteoporosis, bone metastasis, or metabolic bone disorders. exclusion criteria: * patients with pelvic ct scans that do not fully display the anatomical structures. * patients younger than 18 years or older than 65 years. * patients with pelvic fractures, deformities, or prior orthopedic surgeries. * patients with incomplete clinical or radiological data. * patients with rheumatologic sequelae, bone metastasis, or metabolic bone diseases.

Keywords: acetabulum fracture virtual study anterior column
a phase i study of bendamustine hydrochloride in patients with indolent b-cell non-hodgkin's lymphoma

Conditions: Non-Hodgkin's Lymphoma

Summary: the purpose of this study is to assess the tolerability, pharmacokinetics and antitumor effect of bendamustine hydrochloride (syb l-0501) in patients with indolent b-cell non-hodgkin's lymphoma.

indolent b-cell non-hodgkin's lymphoma is treated mainly with radiation and chemotherapy using a combination of chemotherapies, such as purine-analogues and chop (cyclophosphamide, doxorubicin, vincristine and prednisolone). after the approval of an antibody therapy agent rituximab®, it alone or combination with chop has been introduced. bendamustine hydrochloride has a unique structure compared with the marketed agents, and has an innovative mechanism of action. thus, it is expected that bendamustine hydrochloride will provide new alternatives for patients with indolent b-cell non-hodgkin's lymphoma.

Eligibility criteria:
inclusion criteria: indolent b cell non-hodgkin's lymphoma patients with prior therapy who satisfy the conditions listed below. no restrictions regarding gender. * patients with histologically or cytologically confirmed indolent b cell non-hodgkin's lymphoma. * patients who had not received treatment (chemotherapy, antibody therapy and radiation/ radiotherapy) for more than 4 weeks following prior therapy and who are judged to carry no effect from the prior therapy. * patients aged from 20 to less than 75 years. * patients who had agreed in-patient during first course therapy. * patients from whom written consent to participate in this study has been obtained. exclusion criteria:patients who meet any of the following criteria will be excluded. * patients with apparent infections. * patients with serious complications (hepatic failure or renal failure). * patients with complication or history of serious heart failure (e.g. cardiac infarction, ischemic heart disease). * patients with serious digestive symptoms (nausea/ vomiting/ diarrhea). * patients who are known to be positive for hbv, hcv or hic. * patients receiving other investigational drugs within 3 months before registration in the study. * patients with allogenic transplant. * women who are pregnant, of childbearing potential, or lactating. * patients who do not agree to contraception. * otherwise, patients who are judged by the investigator as being unsuitable for inclusion in the study.

Keywords: non-hodgkin's lymphoma malignant lymphoma
pharmacokinetic and pharmacodynamic study of a single-dose of pf-04950615 (rn316) in combination with atorvastatin

Conditions: Hypercholesterolemia; Dyslipidemia

Summary: the primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of pf-04950615 (rn316) in volunteers on stable doses of atorvastatin. pf-04950615 (rn316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.


Eligibility criteria:
inclusion criteria: * on stable doses of atorvastatin (40 mg daily) for 45 days prior to day 1. * bmi 18.5 to 40 kg/m2 inclusive, and body weight equal or lower than 150 kg. exclusion criteria: * history of a cardiovascular event (e.g., mi ) during the past year. * poorly controlled type 1 or type 2 diabetes mellitus (definition: uncontrolled diabetes is defined as hbiac \>9%). * poorly controlled hypertension (uncontrolled hypertension is defined as a systolic blood pressure greater than 140 mm hg or a diastolic blood pressure greater than 90 mm hg, even with treatment). subjects who have hypertension and are controlled on stable dosages of anti-hypertensive medications can be included.

Keywords: hypercholesterolemia dyslipidemia ldl cholesterol high cholesterol pf-04950615 rn316
views on sharing family medical history in healthy women undergoing mammograms or breast evaluation

Conditions: Breast Cancer

Summary: rationale: learning about the concerns that individuals may have about providing family medical history online for genetic risk assessment or research may help doctors plan future research. purpose: this clinical trial is studying views on sharing family medical history in healthy women undergoing mammograms or breast evaluation.

objectives: * to gain an initial understanding of the ethical, family, and related concerns that individuals may have when offered the option of providing family medical history online for genetic risk assessment or research. * to identify specific directions for future research into the ethics of online genetic risk assessment. outline: participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. participants' feelings about whether or not to use an online genetic assessment tool (i.e., genetic risk easy assessment tool \[great\]) are explored. the great allows for the electronic creation, analysis, and dissemination of family histories of individuals who may be at risk for various types of cancer. key factors influencing a participant's use of the tool, including concerns about confidentiality, privacy, informed consent, access to risk information, and security of online family history databases, are explored. ethical issues regarding communication and agreement among family members on disclosing family medical history are also discussed.

Eligibility criteria:
disease characteristics: * healthy women undergoing mammograms or being evaluated for a breast concern at the university hospitals breast center patient characteristics: * able to speak english prior concurrent therapy: * not specified

Keywords: breast cancer
tranexamic acid in sleeve gastrectomy

Conditions: Tranexamic Acid Adverse Reaction

Summary: the effectiveness of tranexamic acid use will be measured in cases of sleeve gastrectomy in bariatric surgery and in early postoperative bleeding.

prospective, comparative and double-blind study with patients aged 18-65 years admitted to bariatric surgery. selected patients were given or not given venous tranexamic acid (txa) during anesthesia induction (cg). anesthesia and thromboprophylaxis protocols were similar between groups. for statistical analysis, χ2 and analysis of variance tests were performed using the spss 21.0 ® statistical program at a significance level of p \< 0.05.

Eligibility criteria:
inclusion criteria: * patients aged 18 to 65 years with an american association of anesthesiologists (asa) physical condition score ii or iii * undergoing bariatric surgery and lsg exclusion criteria: * history of thromboembolic disease or severe comorbidity (asa iv or more) * platelet antiaggregants or anticoagulants * active intravascular coagulation carriers * acute occlusive vasculopathy * hypersensitivity to the components of the txa formula.

Keywords: tranexamic acid sleeve gastrectomy postoperative bleeding
comparison of stavudine used alone or in combination with didanosine in hiv-infected children

Conditions: HIV Infections

Summary: to evaluate the safety and determine the pharmacokinetic disposition of stavudine (d4t) alone and in combination with didanosine (ddi), and whether concurrent administration alters the disposition of either drug. to compare d4t versus d4t plus ddi with respect to short and long term changes from baseline in plasma hiv rna concentrations. to determine the relationship, if any, between drug exposure and viral burden. in a pilot study of d4t and ddi given to eight children with advanced hiv for 24 weeks, the three children with baseline counts greater than 50 cells/micro liter experienced a 20% increase in their cd4+ lymphocyte counts. based on these results, controlled trials of the same regimen for children with less advanced hiv disease should be undertaken.

in a pilot study of d4t and ddi given to eight children with advanced hiv for 24 weeks, the three children with baseline counts greater than 50 cells/micro liter experienced a 20% increase in their cd4+ lymphocyte counts. based on these results, controlled trials of the same regimen for children with less advanced hiv disease should be undertaken. eligible subjects receiving d4t will be assigned in an open manner to arm 1, and subjects who have been receiving zidovudine (azt) will be assigned in a randomized, double blind manner to arms 2 and 3. each subject will receive study drug for 48 weeks as follows: arm 1 - d4t plus ddi, arm 2 - d4t alone, arm 3 - d4t plus ddi.

Eligibility criteria:
inclusion criteria patients must: * be on-study, on-treatment in actg 240, or receiving azt monotherapy by prescription for at least 6 months immediately preceding enrollment. * have laboratory evidence of hiv-1 infection \ = 18 months - 2 positive viral tests or 2 or more positive tests for hiv antibody * have parent or legal guardian willing to sign a consent. prior medication: required: * on-study, on-treatment in actg 240 (d4t or azt) or receiving azt monotherapy by prescription for at least six months immediately preceding this trial. exclusion criteria co-existing condition: patients with any of the following symptoms or conditions are excluded: * intractable diarrhea or vomiting. * current clinical or laboratory grade 3 or worse toxicities. concurrent medication: excluded: * concurrent use of antiretroviral agents other than those provided by the study, immunomodulators (other than ivig or corticosteroids), or other investigational drugs except for those in actg 254 and actg 219. * chemotherapy for active malignancy. patients with any of the following prior conditions are excluded: * reached an actg 240 defined endpoint, or are permanently off actg 240 study treatment. * prescription azt recipients may not have received \> 6 weeks of d4t or ddi previously. * subjects who have had chemotherapy for active malignancy. prior medication: excluded: * prescription azt recipients may not have received \> 6 weeks of d4t or ddi previously.

Keywords: didanosine drug therapy, combination antiviral agents stavudine
safety and efficacy of telbivudine on liver cirrhosis in patients with chronic hepatitis b (chb)

Conditions: Liver Cirrhosis; Chronic Hepatitis B

Summary: antiviral treatment on chronic hepatitis b (chb) patients with liver cirrhosis is compulsory and effective. telbivudine, which is superior to lamivudine in the treatment of chb,is considered to be appropriate for the antiviral treatment on chb patients with liver cirrhosis.

antiviral therapy on chb patients with liver cirrhosis is compulsory and effective. diseases development can be prevented or delayed if the virus is depressed successfully. lamivudine is often used and usually has good efficacy. however, lamivudine resistance and virus mutation happens a lot. telbivudine, which is superior to lamivudine in the treatment of chb,is considered to be appropriate for the antiviral treatment on chb patients with liver cirrhosis.

Eligibility criteria:
inclusion criteria: * liver cirrhosis with chb * without history of antiviral therapy or discontinued antiviral therapy for more than 6 months * for patients with compensated liver cirrhosis: hbv dna≥4log copies/ml if hbeag positive,hbv dna≥3log copies/ml if hbeag negative * for patients with uncompensated liver cirrhosis:hbv dna positive exclusion criteria: * coinfection with hcv,hdv and hiv * afp≥100mg/l or hcc diagnosed by iconography * with severe cardiovascular, respiratory and endocrinology diseases or autoimmune diseases

Keywords: liver cirrhosis chronic hepatitis b antiviral therapy telbivudine